A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke;Una polipastilla para todos? Un examen crítico de la literatura sobre la polipastilla parala prevención primaria de enfermedades cardiovasculares y derrames cerebrales

Annals of Pharmacotherapy

Volumn 46, Issue 5, 2012, Pages 688-695

  Carey, Katherine M ^a   Comee, Morgan R ^a   Donovan, Jennifer L ^a   Kanaan, Abir O ^a  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Cardiovascular Disease; Polycap; Polypill; Primary Prevention; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS ATENOLOL PLUS HYDROCHLOROTHIAZIDE PLUS RAMIPRIL PLUS SIMVASTATIN; ACETYLSALICYLIC ACID PLUS ATORVASTATIN PLUS ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; POLYCAP; RAMIPRIL; RED HEART PILL 2B; SIMVASTATIN; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; COUGHING; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTENSION; LOW DRUG DOSE; PATIENT COMPLIANCE; PILL; POLYPHARMACY; POLYPILL; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; STROKE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENTS; ASPIRIN; ATENOLOL; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; HUMANS; HYDROCHLOROTHIAZIDE; HYPOLIPIDEMIC AGENTS; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; RAMIPRIL; SIMVASTATIN; STROKE;

EID: 84860994479     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q621     Document Type: Review

References (32)

1. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419-1424. DOI 10.1136.bmj.326.7404.1419
2. Yusuf S, Pais P, Afzal R, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomized trial. Lancet 2009;373:1341-1351. DOI 10.1016/S0140-6736(09)60611-5
3. Cadila Pharmaceuticals Limited. Polycap. http://www.polycap.org/in-dex.html (accessed 2011 Sept 27).
4. Hughes S. New polypill data predict a halving of CV events. http://www.theheart.org/article/1231481.do; 2011 May 26 (accessed 2011 Dec 16).
5. Taylor F, Ward K, Moore THM, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2011;1:CD004816. DOI 10.1002/14651858.CD004816.pub4
6. Greving J P, Visseren FLJ, de Wit GA, Algra A. Statin treatment for primary prevention of vascular disease: whom to treat? Cost-effectiveness analysis. BMJ 2011;342:d1672. DOI 10.1136/bmj.d1672
7. Baigent C, Sudlow C, Collins R, et al. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocar-dial infarction, and stroke in high risk patients. BMJ 2002;324:71-86. DOI 10.1136/bmj.324.7329.71
8. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 2001;85:265-271. DOI 10.1136/heart.85.3.265
9. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002;136:161-172.
10. Bartolucci AA, Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2006;98:746-750. DOI 10.1016/j.amjcard.2006.04.012
11. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306-313. DOI 10.1001/jama.295.3.306
12. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-1860. DOI 10.1016/S0140-6736(09)960503-1
13. Fowkes FGR, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a population screened for a low ankle brachial index. JAMA 2010;303:841-848. DOI 10.1001/jama.2010.221
14. Belch J, MacCuish A, Campbell I, et al. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337: a1840. DOI 10.1136/bmj.a1840
15. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300:2134-2141. DOI 10.1001/jama.2008.623
16. Greving J P, Buskens E, Koffijberg H, Algra A. Cost-effectiveness of as pirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation 2008;117:2875-2883. DOI 10.1161/CIRCULATIONAHA.107.735340
17. Verdecchi P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005;46:386-392. DOI 10.1161/01.HYP.0000174591.42889.a2
18. Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hy-drochlorothiazide: a retrospective cohort analysis. Hypertension 2011;57:689-694. DOI 10.1161/HYPERTENSIONAHA.110.161505
19. Multiple Risk Factor Intervention Trial Research Group. Coronary heart disease death, nonfatal acute myocardial infarction and other clinical outcomes in the multiple risk factor intervention trial. Am J Cardiol 1986; 58:1-13. DOI 10.1016/0002-9149(86)90232-8
20. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006;47:352-358.
21. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423-1429. DOI 10.1136/bmj.326.7404.1423
22. Wald DS, Law MR, Morris JK. Homocysteine and cardiovascular dis ease: evidence on causality from a meta-analysis. BMJ 2002;325:1202-1208. DOI 10.1136/bmj.325.7374.1202
23. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-1577. DOI 10.1056/NEJMicm050780
24. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomized trials. BMJ 2003;346;1427-1434. DOI 10.1136/bmj.326.7404.1427
25. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-1913. DOI 10.1016/S0140-6736(02)11911-8
26. Patel A, Shah T, Shah G, et al. Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (Polycap). Am J Cardiovasc Drugs 2010;10:95-103. DOI 10.2165/11532170-000000000-00000
27. The National Institute for Health and Clinical Excellence. Clinical management of primary hypertension in adults (NICE clinical guideline 127). http://www.nice.org.uk/nicemedia/Live/13561/56008/56008.pdf; 2011 (accessed 2012 Jan 15).
28. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Car-diol 2008;52:1482-1489. DOI 10.1016/j.jacc.2008.06.048
29. Malekzadeh F, Marshall T, Pourshams A, et al. A pilot double-blind randomized placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors. Int J Clin Pract 2010; 64:1220-1227. DOI 10.1111/j.1742-1241.2010.02412.x
30. Soliman EZ, Mendis S, Dissanayake WP, et al. A polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Trials 2011;12:3. DOI 10.1186/1745-6215-12-3
31. Rodgers A, Patel A, Berwanger O, et al. An international randomized placebo-controlled trial of a four-component combination pill ("polyp-ill") in people with raised cardiovascular risk. PLoS ONE 2011;6: e19857. DOI 10.1371/journal.pone.0019857
32. Muntner P, Mann D, Wildman RP, Shimbo D, Fuster V, Woodward M. Projected impact of polypill use among US adults: medication use, cardiovascular risk reduction, and side effects. Am Heart J 2011;161:719-725. DOI 10.1016/j.ahj.2010.12.019